ADAPTIVE AND INNATE IMMUNE RESPONSES
TRIGGERED TO NEUTRALIZE GASTRIN HORMONES
AS A THERAPY FOR GI CANCERS

Stacks Image 6
Fred Jacobs, BSc, CPA (Founder)
Chief Executive Officer
Managing Director


Fred earned his accounting degree at the University of Maryland and started his professional career with PwC in the Washington DC office where he worked on significant assignments like the audit and divestiture of ATT. Fred was transferred to the Honolulu, Hawaii office of PwC to work with Pacific Rim clients. Fred moved to healthcare as the Chief Operating Officer of Island Care, a US Health Maintenance Organization. While at Island Care, Fred was instrumental in the pre-IPO activities for a biotechnology company called Aphton Corporation. Aphton corporation had its IPO and listed on the Nasdaq market, in 1991. Fred became their Chief Financial Officer. Aphton raised $230M that was invested in gastrin hormone therapy and other hormone therapies. Capitalizing on that experience, Fred co-founded Astrimmune to carry on the important work of gastrin hormone neutralisation. Fred co-founded TYG Oncology to enable the development of TYG100, a product that promises to provide a well tolerated non-chemo alternative or adjuvant for pancreatic cancer patients and for other gastrointestinal cancers, using gastrin neutralisation therapy.

Stacks Image 254

Christof Langer, MSc, MBA (Founder)
Non-Executive Director Operations

Christof Langer received an international engineering degree in food- and biotechnology (MSc) from the Vienna University of A pplied Sciences in 1996. In the same year he started his professional career at Baxter BioScience where he held various leading positions in the area of pharmaceutical production Management . 2001 he was promoted to head of production in Vienna; in 2002 he was announced “Director Manufacturing”. In this role he successfully completed a 2 year training to become a Lean-Six-Sigma Black Belt. In 2004, he moved to the Czech Republic to start up and lead Baxter‘s newly built Czech vaccines entity Baxter s.r.o. as “Managing Director”. Starting in 2006, he took responsibility as “Managing Director” in Neuchatel, Switzerland, for Baxter’s blockbuster manufacturing facility Baxter BioScience sarl. After returning to Austria in 2009, he founded an operations & strategy consulting firm whilst preparing for the foundation of S-TARget therapeutics in 2010. Since 2010 he serves as CEO of S-TARget therapeutics. In 2013 he co-founded OncoQR ML OG, a Biotech Start-up developing top products in the fields of oncology, autoimmune diseases and infectious diseases. At TYG Oncology Ltd, a joint venture of OncoQR and Astrimmune Ltd, he serves as COO.

Stacks Image 9
Geert C. Mudde, PhD (Founder)
Non-Executive Director Technology / Science

Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions such as “Deputy Head of the Immunology Department” at the Novartis Research Institute in Vienna, Austria, “Director of Allergy and Inflammation/Immunology” at the Parke Davis Research Institute in Fresnes, France, “Director Immunology” at Ingenium Pharmaceuticals, Martinsried, Germany, and “VP Exploratory Research” at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim “Director Discovery Research”, Dr. Mudde co-founded the biotech company f-star GmbH, where he served as “Chief Scientific Officer”  until 2009, when he started to prepare for the foundation of S-TARget therapeutics. Since 2010 he serves as CSO of S-TARget therapeutics. In 2013 he co-founded OncoQR ML OG together with Christof Langer. At TYG Oncology Ltd, he serves as well as CSO.


Stacks Image 267
Paul Broome, MB, ChB, FFPM, (Founder)
Chief Medical Officer
Managing Director

Paul was Vice President, Medical Director, Clinical Trials and Regulatory Affairs for Aphton (1994-2006) following 15 years working with major pharmaceutical companies. Initially, Dr Broome established pre-clinical, manufacturing and QC in Europe for Aphton’s early studies, then was responsible for European and Asian clinical and regulatory operations, later assuming worldwide clinical and regulatory management.  He has continued to work on anti-gastrin vaccines, establishing Tyg with partners in 2012 to develop  the most successful construct to date.
[Sleeker_special_clear]